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Depressive symptoms in diabetes are associated with reduced self-care, glycae-
mic control and health-related quality of life (hrQOL) and increased diabetes-spe-
cific distress. We analysed if the recovery from depressive symptoms would be 
associated with improvements in these aspects. 182 diabetes patients (age 45 ± 
14 y.; 57% female; BMI 29 ± 7; 62% type 1 diabetes; illness duration 15 ± 11 y.; 
95% with insulin; HbA1c 8.8 ± 1.7%) with subclinical depressive symptoms (CES-D 
score ≥ 16 without meeting criteria for clinical depression; mean CES-D score: 23 
± 8) participated in a prospective study. Recovery was defined as CES-D score < 16 
at 12-month follow up. Dependent variables were diabetes self-care (SDSCA), gly-
caemic control (HbA1c), diabetes distress (PAID) and hrQOL (SF-36). We compa-
red baseline-to-follow up changes between recovered versus non-recovered pati-
ents using ANCOVA (adjusted for baseline values). At follow up, 85 patients (47%) 
showed recovery. The mean reduction of depressive symptoms in this group was 
–13 ± 9 CES-D scale points; the mean change in the 97 patients remaining de-
pressed (53%) was +2 ± 9 CES-D scale points. Recovered patients compared to un-
recovered ones showed significantly greater improvement (baseline-to-follow up 
change) regarding self-care (+0.14 ± 1.11 vs. –0.19 ± 1.05 SDSCA scale points, Δ = 
0.31, P = 0.014), glycaemic control (–0.78 ± 2.19 vs. –0.56 ± 1.53 HbA1c %-points, Δ 
= 0.12, P = 0.042), diabetes distress (–13.6 ± 18.8 vs. –4.4 ± 17.1 PAID scale points, 
Δ = 0.51, P < 0.01) and hrQOL (physical hrQOL: +2.0 ± 8.7 vs. –1.1 ± 9.6 T scores, Δ 
= 0.34, P = 0.005; mental hrQOL: +14.5 ± 11.9 vs. +0.1 ± 12.2 T scores, Δ = 1.19, P < 
0.01). This study provides evidence that recovery from depressive symptoms may 
have positive impact on diabetes control, diabetes-specific distress and quality of 
life.
Table 1:   Sample characteristics at baseline
Depressive disorders are a frequent comorbid condition in people with diabetes with 
an estimated prevalence about of 11 – 16%. Additionally, an even larger percentage 
of patients report elevated depressive symptoms without meeting full diagnostic cri-
teria for a depressive disorder. Studies assessing negative impact of comorbid depres-
sion in diabetes found significantly reduced self-care activities, glycaemic control and 
long-term prognosis compared to people with diabetes without depressive symptoms. 
Health-related quality of life was also found to be greatly impaired in this group. Nota-
bly, evidence of negative impact of comorbid depression was found not only in people 
with clinical depressive disorders but also subclinical forms such as minor depression. 
In sum, these findings suggest that depressive symptoms predict poorer health outco-
mes and quality of life in people with diabetes.
Based on this evidence, a number of studies aimed to improve diabetes-related health 
outcomes in these patients through behavioural or pharmacological treatment for de-
pression. However, few studies were able to demonstrate significant treatment effects 
on medical outcomes such as glycaemic control, and the overall evidence of benefits 
gained through the reduction of depressive symptoms is largely inconsistent. On the 
other hand, obtaining a treatment does not need to indicate adequate recovery from 
depression, even if the mean between-group treatment effect was significant. In fact, 
the potential benefits of recovery from depression regarding health outcomes might 
be more reliably estimated through a direct comparison between patients with large 
versus small changes in depression levels instead of comparisons between treatment 
groups. To assess associations between recovery from depressive symptoms and poten-
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• At 12-month follow up, 85 of the patients (47%) showed CES-D scores lower than 
16 indicating recovery from depressive symptoms (see figure 1). The mean reduc-
tion of depressive symptoms in this group was –12.9 ± 9.1 CES-D scale points; the 
mean change in the 97 patients remaining depressed (53%) was +1.6 ± 9.4 CES-D 
scale points.
• Patients who recovered from depressive symptoms (follow up CES-D scores < 16) 
showed significantly greater improvement (baseline-to-follow up change) than tho-
se with persistent depressive symptoms regarding self-care (+0.14 ± 1.11 vs. ¬–0.19 
± 1.05 SDSCA scale points, Δ = 0.31, P = 0.014) and glycaemic control (–0.78 ± 2.19 
vs. –0.56 ± 1.53 HbA1c %-points, Δ = 0.12, P = 0.042). Moreover, they showed sig-
nificantly greater improvement in physical and mental health-related quality of life 
(physical hrQOL: +2.0 ± 8.7 vs. –1.1 ± 9.6 T scores, Δ = 0.34, P = 0.005; mental hr-
QOL: +14.5 ± 11.9 vs. +0.1 ± 12.2 T scores, Δ = 1.19, P < 0.001) as well as diabetes-
specific distress (–13.6 ± 18.8 vs. –4.4 ± 17.1 PAID scale points, Δ = 0.51, P < 0.001); 
results are displayed in figure 2.
• If the criterion for depressive symptoms was set at a higher cut-off score of ≥ 22 in 
the CES-D scale, indicative of more severe depressive symptoms (this score shows 
the best likelihood ratio for depression in the German population), 104 patients 
(57% of the sample) met the criterion at baseline and 58 patients (32%) showed 
relevant recovery at follow up (CES-D score ≥ 22 at baseline and < 22 at follow up; 
see figure 1). The mean reduction in this group was –16.9 ± 8.0 CES-D scale points 
while the mean change in the 124 remaining patients was +0.3 ± 8.8 points.
• Patients in this ‘recovered group’ (CES-D score ≥ 22 at baseline and < 22 at follow 
up) showed greater improvement regarding self-care (+0.29 ± 1.02 vs. ¬–0.18 ± 
1.09 SDSCA scale points, Δ = 0.45, P = 0.007) and glycaemic control (–1.08 ± 2.31 
vs. –0.48 ± 1.60 HbA1c %-points, Δ = 0.30, P = 0.055), although the latter result 
bordered on significance. They also showed greater improvement in health-related 
quality of life (physical hrQOL: +2.3 ± 9.9 vs. –0.5 ± 8.9 T scores, Δ = 0.30, P = 0.055; 
mental hrQOL: +16.3 ± 11.5 vs. +2.4 ± 12.9 T scores, Δ = 1.14, P < 0.001) as well as 
diabetes-specific distress (–20.1 ± 16.8 vs. –3.5 ± 16.8 PAID scale points, Δ = 0.99, P 
< 0.001); results are displayed in figure 3.
Figure 3:  Baseline-to-follow up changes in patients who recovered versus did not recover under 
the CES-D cut-off scores of 22
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Figure 1:  Course of depressive symptoms over 12 months and rates of recovery under the CES-D 
cut-off scores of 16 and 22 respectively
Figure 2:  Baseline-to-follow up changes in patients who recovered versus did not recover under 
the CES-D cut-off scores of 16
This study provides evidence that recovery from depressive symptoms may have positi-
ve impact on diabetes self-care behaviour and medical health outcomes such as glycae-
mic control. Additionally, people with diabetes who recovered from depressive sym-
ptoms reported significant improvements regarding health-related quality of life and 
diabetes-specific distress. The finding of increased self-care and glycaemic control is of 
particular interest as many studies struggled to find associations between depression 
treatments and improvements in these outcomes. Notably, we found stronger impro-
vements in these variables when setting the criterion for recovery at a higher depres-
sion score, suggesting that particularly the recovery from strong depressive symptoms 
or depressive disorders may yield benefits regarding diabetes-related health outcomes 
(the fact that the ‘glycaemic  control improvement’ [Δ = 0.30] in this comparison bor-
dered on significance [P = 0.055] is a limitation but can be explained by lacking statis-
tical power due to small sample size [n = 58]). We hypothesised that such benefits of 
recovery from depression might be more reliably estimated through a direct compari-
son between patients with large versus small changes in depression levels, which was 
supported in this study. Against this background, future treatment studies regarding 
depression in diabetes might be well advised to not only examine between-group ef-
fects on health outcomes but to compare ‘responders’ (regardless of whether verum- 
or placebo-treated) to those remaining symptomatic. In sum, our findings suggest that 
effective treatments of depression in diabetes can indeed yield positive effects on me-
dical outcomes.
tial changes in diabetes-related health outcomes in people with diabetes, we analysed 
data from the DIAMOS study, a randomised controlled trial testing a diabetes-specific 
cognitive-behavioural treatment for subclinical depression.
182 people with diabetes (age 45 ± 14 years; 57% female; BMI 29 ± 7 kg/m2; 62% 
type 1 diabetes; illness duration 15 ± 11 years; 95% with insulin treatment; HbA1c 8.8 
± 1.7% [73 ± 19 mmol/mol]; see table 1) with subclinical depressive symptoms (defi-
ned as having a CES-D score ≥ 16 without meeting DSM-IV criteria for major depressi-
on; mean CES-D score was 23 ± 8) participated in a prospective trial (DIAMOS study; 
identifier NCT01009138). Recovery from depressive symptoms was defined as having a 
CES-D score < 16 at 12-month follow up. Dependent variables (diabetes-related health 
outcomes) were diabetes self-care (Summary of Diabetes Self-Care Activities Measure 
[SDSCA]), glycaemic control (HbA1c), physical and mental health-related quality of life 
(Short Form-36 Health Survey [SF-36]) and diabetes-specific distress (Problem Areas in 
Diabetes Scale [PAID]). We compared baseline-to-follow up changes between recovered 
versus non-recovered patients using ANCOVAs (adjusted for baseline group differences 
of the outcome variables).
